Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1693 - Quantitation of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentration (sTK1) (81P)


18 Nov 2017


Poster lunch


Cytotoxic Therapy;  Translational Research;  Breast Cancer


Bernhard Tribukait


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


B. Tribukait1, K.K. Jagarlamudi2, J. Bergh1, T. Hatschek1

Author affiliations

  • 1 Oncology/pathology, Karolinska Institutet, 17176 - Stockholm/SE
  • 2 Biology, AroCell, 754 50 - Uppsala/SE


Abstract 1693


NACT of early breast cancer (BC) is intended to facilitate less extensive surgery by downstaging and provides the opportunity to study tumor response due to treatment. TK1 has a key function in DNA synthesis and repair responsible for maintaining the nucleoid pool balance by salvage and recycle thymidine from extracellular sources. Normally, TK1 is synthesized during S-phase, inactivated at mitosis and not leaked in connection with cell death. In contrast, release of TK1 into blood by necrosis or apoptosis is typical in malignancies.


We quantified cell loss using TK210 ELISA® for serial measurements of sTK1 in blood from 145 BC patients undergoing epirubicin/docetaxel +bevacizumab NACT therapy. sTK1 was related to clinical/radiological response after cycle (Cy) 2, 4 and 6, pathologic response, and disease free survival.


Base-line sTK1 3-doubles 48h after treatment to plateau levels but declines during the 3 weeks rest between courses. sTK1 measured after treatment arrest periods correlated, after 4 cycles of treatment, significantly with clinical/radiological response during treatment and pathologic response at surgery. Surprisingly, the 48 h plateau values are highest in pT0, followed by pT3, pT2 and lowest in pT1. Disease free survival (median follow-up 49 mo.) ranged between 29.7% in pT0 and 5.7% in pT1 and is significantly related to sTK1.


Proliferation and cell loss are responsible for tumor growth and response to therapy. By now, no quantitation methods for cell loss are available. In this study TK1 has been proven to be a significant predictor of treatment response in NACT. sTK1 is a promising method for treatment related response and clinical drug development.

Clinical trial identification

EudraCT Number: 2007-005858-23

Legal entity responsible for the study

Karolinska Institute


Karolinska Institute


B. Tribukait: The author has stocks in AroCell. K.K. Jagarlamudi: I am working at AroCell AB.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.